Expression and modulation of Rho kinase in human pregnant myometrium

C.J. Moran¹, A.M. Friel¹,², T.J. Smith², M. Cairns² and J.J. Morrison¹

¹Department of Obstetrics and Gynaecology, National University of Ireland Galway, Clinical Science Institute, University College Hospital, Newcastle Road, Galway and ²National Diagnostics Centre, BioResearch Ireland, National University of Ireland Galway, University Road, Galway, Ireland

To whom correspondence should be addressed. E-mail: john.morrison@nuigalway.ie

There is little information outlining the role of Rho kinase, RhoA, and calcium sensitization in regulation of human uterine contractility during pregnancy. The aims of this study were to investigate the expression of RhoA, and the Rho kinases ROCK I and ROCK II in human pregnant myometrium, to evaluate the effects of Rho kinase inhibition on human pregnant myometrial contractility in vitro, and to compare these effects with those of the calcium channel blocker nifedipine. RT–PCR using primers for RhoA, ROCK I and ROCK II was performed on mRNA isolated from human pregnant myometrium. Isometric recording was performed in isolated myometrial strips obtained at Caesarean section. The effects of the Rho kinase inhibitor Y-27632 (1 nmol/l to 10 mmol/l), and nifedipine (1 nmol/l to 10 mmol/l), on oxytocin (0.5 nmol/l) induced contractions were measured and compared. Expression of RhoA, ROCK I and ROCK II mRNA was identified in human pregnant myometrium (n = 3). Y-27632 exerted a potent relaxant effect on myometrial contractility with a pD₂ value (± SEM) of 7.63 ± 0.38 (n = 6). The maximum net relaxant effect (± SEM) was 72.3 ± 6.1% (n = 6). Corresponding values for nifedipine were 7.24 ± 0.48 (n = 6; P = 0.469) and 93.40 ± 3.1% (n = 6; P = 0.028). Rho A/Rho kinase-mediated calcium sensitization may play role in the physiology of human parturition, and pharmacological inhibition of this pathway may therefore provide a novel approach to tocolysis for pre-term labour.

Key words: human myometrium/preterm labour/Rho kinase/tocolysis

Introduction

The delivery of infants preterm is a major cause of perinatal morbidity and mortality in current obstetric practice (Goldenberg and Rouse, 1998). A significant proportion of all preterm deliveries (~30–50%) is related to spontaneous idiopathic preterm labour (Ianuchi et al., 1996; Burke and Morrison, 2000). At present, no satisfactory therapeutic intervention exists for this clinical problem (Morrison and Rennie, 1997). Due to the poor efficacy of currently available tocolytic agents, attempts to address this problem clinically have been largely unsuccessful (Goldenberg and Rouse, 1998; Gyetvai et al., 1999). There is therefore a need to investigate scientifically novel methods of uterine relaxation where tocolytic potential may be identified.

The state of contractility of smooth muscle is regulated by both intracellular calcium concentration ([Ca²⁺]ᵢ) and by the calcium sensitivity of myofilaments (Wray, 1993). For the former mechanism, an increase in [Ca²⁺]ᵢ results in phosphorylation of myosin light chain (MLC) catalysed by the calcium–calmodulin-activated myosin light chain kinase (MLCK). The process of calcium sensitization refers to an increase in smooth muscle tension and/or phosphorylation of MLC at a constant [Ca²⁺]ᵢ. Smooth muscle relaxation occurs as a result of dephosphorylation of myosin light chains by a phosphatase known as myosin light chain phosphatase (MLCP).

For calcium sensitization, it is now clear that a small G-protein, RhoA, is associated with inhibition of MLCP (Uehata et al., 1997; Kunihiko et al., 1999). RhoA is a monomeric G-protein which is active when it contains GTP and inactive when the bound nucleotide is GDP (Somlyo and Somlyo, 2000). Although the precise mechanism of action has not been fully elucidated, two target proteins of RhoA, rho-associated coil-forming protein kinase (ROCK I, also called p160ROCK), and its isoform, ROCK II (also known as ROKα or Rho kinase) have been reported as having a key role in the RhoA-mediated Ca²⁺ sensitization. These target proteins are collectively known as Rho kinases and their activation enhances RhoA-mediated calcium sensitization and smooth muscle contractility. In recent years, specific inhibitors of Rho kinases have been investigated as smooth muscle relaxant agents (Kawada et al., 1999; Ishizaki et al., 2000). Y-27632 [(+)-(R)-trans-4-(1-aminoethyl-N-4-pyridyl)cyclo-
hexanecarboxamide dihydrochloride] is widely used as a specific inhibitor of the ROCK family of protein kinases (ROCK I and II) (Fu et al., 1998; Nakahara et al., 2000; Sward et al., 2000). It appears that it exerts this activity by competing with ATP for binding to the kinases (Ishizaki et al., 2000).

There are no data outlining the expression of RhoA, ROCK I or ROCK II in human pregnant myometrium or the effects of ROCK inhibition on myometrial contractility. The aims of this study were to investigate the expression of RhoA, ROCK I and ROCK II in human pregnant myometrium, to evaluate the effects of the Rho kinase inhibitor Y-27632 on contractions of human isolated myometrium during pregnancy and to compare these effects with those of the calcium channel blocker nifedipine.

Materials and methods

Tissue collection

Biopsies of human myometrial tissue during pregnancy were obtained at elective Caesarean section. The biopsies were excised from the upper lip of the lower uterine segment incision in the midline, i.e. upper portion of lower uterine segment. Ethical committee approval for the study was obtained from the Research Ethics Committee at University College Hospital, Galway and recruitment was by written informed consent. All Caesarean sections were performed at term (38–41 weeks gestation), prior to the onset of labour. Immediately upon collection, tissue was placed in Krebs–Henseleit physiological salt solution of the following composition: KCl 4.7 mmol/l, NaCl 118 mmol/l, MgSO4 1.2 mmol/l, CaCl2 1.2 mmol/l, KPO4 1.2 mmol/l, NaHCO3 25 mmol/l and glucose 11 mmol/l (Sigma–Aldrich, Dublin, Ireland). Tissue for in-vitro contractility studies was stored at 4°C and used within 12 h of collection. For RNA extraction/RT–PCR, myometrial tissues (n = 3) were rinsed in normal saline immediately upon receipt, snap-frozen in liquid nitrogen and stored at −70°C.

Tissue bath experiments

Longitudinal myometrial strips were dissected, measuring ~2×2×10 mm, and mounted under 2 g of tension in organ bath chambers for isometric recording as previously described (Morrison et al., 1993; Slattery et al., 2001). The tissue baths contained 20 ml of Krebs–Henseleit physiological salt solution which was maintained at 37°C, pH 7.4 and gassed continuously with a mixture of 95% O2/5% CO2. Myometrial strips were allowed to equilibrate for at least 1 h before the addition of oxytocin as a utero-tonic agent. The Krebs–Henseleit physiological salt solution in the tissue baths was changed every 15 min during the equilibration period.

After equilibration, contractions were stimulated by bath exposure of the strips to oxytocin (0.5 nmol/l). The mechanical response of tissues was measured by calculation of the integral of selected areas for 20 min periods using the PowerLab hardware unit and Chart v3.6 software (AD Instruments, Hastings, UK). The integrated tension for the first 20 min after bath addition of oxytocin was calculated and this value served as a control since no significant spontaneous reduction in myometrial contractility was observed over the duration of experiments in control strips. The Rho kinase inhibitor Y-27632, or the calcium-channel blocker nifedipine, were then added to the bath, in a cumulative manner, at increasing bath concentrations (1 nmol/l, 10 nmol/l, 100 nmol/l, 1 µmol/l, 10 µmol/l and 100 µmol/l) at 20 min intervals. The cumulative increases in bath concentration of Y-27632 or nifedipine were achieved in a pattern of one log molar increase every 20 min (i.e. 1 nmol/l, 10 nmol/l, 100 nmol/l etc.). This allowed for a maximum bath exposure of the strip to utero-relaxant of 100–120 min. Control experiments testing for tachyphylaxis revealed no difference between isolated exposure and cumulative exposure during this time. A separate series of experiments using vehicle only was performed. The effects of Y-27632 and nifedipine were assessed by comparing the integral calculated during the 20 min period following addition of each drug concentration as a percentage of the integral obtained in the 20 min period prior to any drug addition (i.e. percentage contractility).

RNA extraction and reverse transcription

Total RNA was isolated using TRIzol reagent (Life Technologies, Grand Island, NY, USA) (Chromczynski, 1993). RNA was then reverse-transcribed into complementary DNA (cDNA) for use as a template for PCR. 1 µg of RNA was DNasel-treated (Life Technologies Inc., Gaithersburg, MD, USA). The RNA samples were then denatured at 65°C for 10 min. Reverse transcription was performed at 42°C for 60 min in a reaction volume of 20 µl containing the following: oligo dT primer (500 ng), Maloney murine leukaemia virus (M-MLV) reverse transcription buffer [50 mmol/l Tris–HCl pH 8.3, 7.5 mmol/l KCl, 3 mmol/l MgCl2, 10 mmol/l diithiothreitol (DTT)] (Promega, Madison, WI, USA), dNTPs (0.1 mmol/l) and 200 IU M-MLV reverse transcriptase (Promega). Reverse transcriptase activity was stopped by heating samples at 65°C for 10 min. Control RNA samples, in which no reverse transcription enzyme was added, were included to confirm that no genomic DNA contamination was present.

PCR

Five µl of this 20 µl reaction was then used in the subsequent PCR. PCR was performed in a final volume of 50 µl containing 1.5 mmol/l MgCl2, 10 mmol/l Tris–HCl, 50 mmol/l KCl pH 8.3 (Boehringer–Mannheim GmbH, Germany), 1.25 U Taq DNA polymerase (Boehringer–Mannheim), 40 µmol/l dNTP (Promega) and 0.2 pmol of each sense and antisense primer. cDNA amplification was carried out by an initial denaturation step of 5 min at 95°C followed by 45 cycles of denaturation at 94°C for 20 s, annealing at 55°C for 45 s and elongation at 72°C for 20 s. A total of 5 µl of each PCR product was then separated by gel electrophoresis on a 1.2% agarose gel. Products were run alongside a 100 bp DNA mass ladder (Sigma, St. Louis, MI, USA) for sizing.

Primers used were designed to published mRNA sequences from GenBank; RhoA accession code L25080, ROCK I accession code XM_008814, ROCK II accession code XM_002676 (Table I).

Drugs and solutions

A stock solution of oxytocin (Sigma–Aldrich, Dublin, Ireland) (1 mmol/l) was made in ethanol. Y-27632 was kindly donated by

---

**Table I. PCR primer sequences**

<table>
<thead>
<tr>
<th>RhoA</th>
<th>Human ROCK I</th>
<th>Human ROCK II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sense</td>
<td>5'-CTCATGTCCTCGAAGGGCCAGT-3'</td>
<td>5'-ATCACCGCAAGACCTCTTATT-3'</td>
</tr>
<tr>
<td>Antisense</td>
<td>5'-ATCATTGCCGAGATCCTTATT-3'</td>
<td>5'-GAAGAAAGAAGAAGGCTCGAGAGAGG-3'</td>
</tr>
<tr>
<td>Sense</td>
<td>5'-GAAGAAAGAAGAAGGCTCGAGAGAGG-3'</td>
<td>5'-ATCATTGCCGAGATCCTTATT-3'</td>
</tr>
<tr>
<td>Antisense</td>
<td>5'-ATCACCGCAAGACCTCTTATT-3'</td>
<td>5'-TTTCTTTTCCCTTGATGAGA-3'</td>
</tr>
</tbody>
</table>
Statistical analysis

Using the calculated integrals of contractile activity at each bath concentration, dose–response curves were analysed by fitting the logistic equation: 

\[ Y = \frac{Y_{\text{max}} \times D}{EC_{50} + D} \]

where \( Y \) is the response (percentage contractility), \( Y_{\text{max}} \) is the maximal relaxation achieved, \( D \) the concentration of agonist (Y-27632 or nifedipine), \( n_4 \) the slope function, and \( EC_{50} \) is the agonist concentration giving the half maximal response. Curve fitting was performed with the software package Prism™ (Graphpad Software, San Diego, USA). Student’s t-test was used to compare pD2 and maximum response values. The statistical package GBSTAT version 6.5 (Dynamic Microsystems, Silver Spring, MD, USA) was used for statistical calculations. A value of \( P < 0.05 \) was accepted as statistically significant.

Results

Myometrial biopsies were obtained from a total of 19 women. All Caesarean sections were performed under regional anaesthesia prior to labour onset. There were no medical complications of pregnancy. Women who had received exogenous prostaglandins or oxytocin were excluded from the study. The demographic details of the women included were as follows: age range 21–38 years (median 33 years); gestation range 38–41 weeks (median 39 weeks); parity 0–4. The reasons for Caesarean section were breech presentation, previous Caesarean section and abnormal fetal position.

The three primer sets yielded PCR products of the expected sizes (\( n = 3 \)) (Figure 1). Amplification with the RhoA primer set resulted in a 309 bp PCR product. This product was sequenced (MWG-Biotech Ltd, Milton Keynes, UK) and the results verified that it was part of the RhoA gene. Amplification of myometrial cDNA with ROCK I and ROCK II primers yielded 369 and 390 bp products which sequence analysis confirmed were part of the ROCK I and ROCK II gene sequences. PCR of the reverse transcriptase-negative controls (RT–) showed no amplification confirming no genomic DNA contamination. Similarly the PCR-negative control (no cDNA template) showed no amplification.

The ROCK inhibitor Y-27632 (1 mmol/l to 100 µmol/l) exerted a potent relaxant effect on myometrial contractility in a concentration-dependent manner in all strips (Figure 2). In Figure 2A, the contractile activity after exposure to oxytocin (0.5 mmol/l) in a control strip is demonstrated. The inhibitory effect of Y-27632 is shown in Figure 2B. The mean pD2 value was 7.63 ± 0.38 and the mean net relaxant effect at maximum bath exposure was 72.3% ± 6.1 (\( n = 6 \)). The calcium channel blocker nifedipine also exerted a potent relaxant effect on myometrial contractility and a representative recording demonstrating this is shown in Figure 2C. The mean pD2 value was 7.24 ± 0.48 and the mean net relaxant effect at maximum bath exposure was 93.4% ± 3.1 (\( n = 6 \)). There was no significant difference between the pD2 values for nifedipine and Y-27632 (\( P = 0.469 \)) (Table II). The mean net maximum relaxant effect for nifedipine (93.4% ± 3.1) was greater than that observed for Y-27532 (72.3% ± 6.1) (\( P = 0.028 \)). The dose–response curves for the effects of Y-27632 and nifedipine on myometrial contractions are shown in Figure 3.

Discussion

The results from this study clearly demonstrate expression of RhoA, ROCK I and ROCK II mRNA in human pregnant myometrium and that the Rho kinase inhibitor Y-27632 results in potent inhibition of human isolated myometrial contractility in tissue obtained in the third trimester of pregnancy. Y-27632 is a highly selective ROCK inhibitor (Uehata et al., 1997; Ishizaki et al., 2000) and therefore results in reduced RhoA-mediated calcium sensitization and inhibition of smooth muscle contractility. This is the first report to our knowledge outlining the effects of ROCK inhibitors on uterine contractility and highlights their potential as novel tocolytic agents. In addition to the potential pharmacological applications of these compounds for inhibition of uterine contractions, our results raise
Rho kinase and human myometrium

Figure 2. Representative recordings of oxytocin-stimulated (0.5 nmol/l) contractions in pregnant human myometrium are shown. (a) Recording from a control strip and no further drug additions were made following incubation with oxytocin. (b and c) Effects of cumulative additions of Y-27632 and nifedipine respectively (1 nmol/l, 10 nmol/l, 100 nmol/l, 1 µmol/l, 10 µmol/l and 100 µmol/l) at 20 min intervals.

Table II. Relaxant effects of Y-27632 and Nifedipine

<table>
<thead>
<tr>
<th></th>
<th>pD₂</th>
<th>Maximum inhibition (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Y-27632</td>
<td>7.6 ± 0.3</td>
<td>72.3 ± 6.1</td>
</tr>
<tr>
<td>(B) Nifedipine</td>
<td>7.2 ± 0.4</td>
<td>93.4 ± 3.1*</td>
</tr>
</tbody>
</table>

*A versus B: P = 0.028.

Values are given for pD₂ and the percentage maximum mean net relaxant effects (± SEM) of Y-27632 and nifedipine on oxytocin-stimulated contractions in human pregnant myometrial tissue. n = number of subjects in each group.

the issue of the possible physiological significance of Rho kinase activity in human myometrium. Little is known about its role in maintenance of uterine quiescence during pregnancy or in regulation of onset and/or maintenance of human parturition. It has been reported that expression of Rho kinase isoforms is up-regulated in rat myometrium in late pregnancy (Niiro et al., 1997). Up-regulation of the proteins for ROCK I and ROCK II has been demonstrated in human pregnant myometrium in comparison to non-pregnant myometrium (Moore et al., 2000). This has led to suggestions that increased endogenous Rho kinase activity, resulting in enhanced RhoA-mediated calcium sensitization, may be involved in the increased contractility that occurs at the time of labour onset at term.

Figure 3. Sigmoidal dose–response curves showing the effects of cumulative additions of Y-27632, and nifedipine (1 nmol/l, 10 nmol/l, 100 nmol/l, 1 µmol/l, 10 µmol/l and 100 µmol/l) at 20 min intervals on oxytocin-stimulated (0.5 nmol/l) contractions on pregnant human myometrium. Percentage contractility is shown on the y-axis and concentration of drug on the x-axis. Open circles represent Y-27632 and closed squares represent nifedipine. Values shown are means and vertical error bars represent SEM.
We compared the effects of Y-27632 with those of nifedipine on isolated human pregnant myometrial contractions. The reasons for this were 2-fold. Nifedipine, in contrast to Y-27632, is a calcium channel blocker and hence reduces intracellular calcium (Saade et al., 1994). Secondly, nifedipine has been used clinically for tocolysis although there are concerns about its efficacy and possible adverse effects (Richichi and Vasilenko, 1992). While Y-27632 was a potent utero-relaxant agent in our studies, we found that nifedipine exhibited a greater mean net relaxant effect. These findings are in agreement with other in-vitro myometrial studies where nifedipine appears to be the most potent uterine relaxing agent (Saade et al., 1994). The possible clinical significance of this is unknown. However, it is clear that the Rho kinase pathway is essential for smooth muscle contractility during the late third trimester of pregnancy. (Fukata et al., 2001) and that future research directed at its role in human myometrium may be of benefit for effective treatment of preterm labour. For clinical tocolysis, clinical trials would be necessary to evaluate potential efficacy and safety.

There are further issues for consideration in the interpretation of our results. Firstly, we did not explore the possibility of an alternative mechanism of action of Y-27632 in achieving myometrial relaxation. Other studies in various tissue systems have revealed that it is a highly selective inhibitor of the Rho kinase enzymes (Uehata et al., 1997; Ishizaki et al., 2000) and hence have indicated its mechanism of action. Secondly, all our studies were carried out in myometrial tissue obtained from the lower uterine segment. While the findings may not similarly apply to myometrial tissue obtained from the uterine fundus, this seems unlikely as there appears to be no difference in contractile properties between myometrial tissues obtained from upper and lower uterine sites (Luckas and Wray, 2000).

In conclusion, RhoA, ROCK I and ROCK II are expressed in human pregnant myometrium and pharmacological inhibition of Rho kinase activity/RhoA-mediated calcium sensitization results in potent relaxation of isolated human myometrial contractility during the late third trimester of pregnancy. Further research is required to elucidate the role of this pathway in the physiology of human parturition and the clinical therapeutic implications for preterm labour.

Acknowledgements

We are grateful to Welfide Corporation, Japan for the gift of Y-27632. We wish to acknowledge the Health Research Board of Ireland, the Higher Education Authority of Ireland and BioResearch Ireland for research funding.

References


